AMULET trial strengthens the case for Lundbeck's Lu AF82422
Danish CNS specialist Lundbeck (LUND: CO) will release clinical data from the AMULET Phase II, double-blind, randomized trial of Lu AF82422 in multiple system atrophy (MSA) at the InternaPional Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024).
Lu AF82422 is a human monoclonal antibody (MAb) that recognizes and binds to all major forms of extracellular alpha-synuclein and thereby is believed to prevent uptake and inhibit seeding of aggregation. Lundbeck says that Lu AF82422 may offer a potential treatment option by targeting the underlying disease pathology of MSA and aiming at slowing clinical progression.
Based on the encouraging AMULET trial outcomes, Lundbeck plans to initiate a Phase III study, following further dialogue with health authorities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze